EMA’s safety committee starts review of cold medicines

,
European Medicines Agency

EMA’s safety committee starts review of cold medicines

Feb 10 (Reuters) – A European Medicines Agency (EMA) committee said on Friday it has started a review of decongestant medicines for cold and flu that contain the ingredient pseudoephedrine following safety concerns.

The EMA said the review was due to reports of conditions affecting blood vessels in the brain in some patients who took pseudoephedrine-containing medicines.

Pseudoephedrine is a drug that is used alone or in combination with other medicines to treat a blocked nose due to cold, flu or allergy.

Makers of pseudoephedrine-containing drugs include Reckitt Benckiser (RKT.L), McNeil Products Ltd. and Organon & Co. (OGN.N).

Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta

Our Standards: The Thomson Reuters Trust Principles.

Source: Reuters

/by
You might also like
European Medicines AgencyEU regulator backs Pfizer’s updated COVID vaccine for XBB.1.5 variant
European Medicines AgencyEU health regulator says COVID pandemic ongoing
Pfizer-BioNTech COVID vaccineEU regulator begins review of Pfizer-BioNTech’s variant-adapted COVID shot
SanofiSanofi, GSK score late win with EU COVID booster approval
amoxicillinWhy Europe’s drug shortages may get worse
COVID-19 maskingEurope to receive Omicron vaccines within days of approval, says MEP
NovavaxEU adds severe allergies as side effect of Novavax COVID vaccine
EnfamilReckitt expects U.S. infant formula shortage until spring